Angel at Forefront of Brain Research

Article excerpt

Byline: By Howard Walker

Medical-research company Angel Biotechnology Holdings has landed a major deal which the Northumberland firm says will move it to the forefront of stemcell manufacturing.

Angel, of Cramlington, has won a contract to make a cell bank for stemcell therapy company ReNeuron's research into the genetic brain disorder Huntington's disease.

While terms of the contract have not been disclosed, Aim-listed Angel says it sees the deal as a big step forward for the company.

Chief operating officer Gordon Sherriff said: "Angel is delighted to have contracted with ReNeuron to provide them with cells manufactured to GMP (good manufacturing practice) for use in subsequent clinical trials. This contract moves Angel to the forefront of stemcell manufacturing."

The cell bank will be made at Angel's GMP lab in Edinburgh, which specialises in the manufacture of cell-based therapeutics and is said by the company to be "rapidly becoming a centre of excellence for stemcell manufacturing". Angel is building a larger pounds 3m factory at its headquarters in Cramlington.

The latest contract win builds on a relationship with ReNeuron. The companies joined forces in a consortium that was awarded a pounds 2.2m, three-year, grant by the Department of Trade and Industry (DTI) in January last year.

The consortium, led by Surrey company ReNeuron, is carrying out a bioprocessing project called "Therapeutic Products from Human Stem Cells" in which Angel is the manufacturing partner. …